EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts

Newton Neidert, Firas Kseibi, William P Martin, Seif Bugazia, Emily Bendel, Cassie Howe, Ryan Helland, Adriana Gregory, Kathleen Liestikow, Timothy Kline, Lisa Vaughan, Vicente E Torres und 1 weitere

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf111 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Newton Neidert und 12 weiteren Autor:innen. Beteiligte Einrichtung: Radiology Department, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Sclerotherapy, Polycystic Kidney, Autosomal Dominant, Cysts, Liver Diseases. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Mayo Clinic, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This medical center migrated from alcohol to sotradecol foam sclerotherapy (SFS) because of perceived improved efficacy in managing symptomatic kidney and liver cysts. We report technical aspects, change in short- and long-term cyst volumes, patient-reported outcomes, safety and applications of the technique.

Methods

In this retrospective observational study, cases from January 2017 to December 2021 had TKCV/TLCV (per Targeted Kidney or Liver or Cyst analysis) segmented using a deep-learning algorithm and cyst segmentation software (pre-, post-procedure and longitudinally). TKCV/TLCV % change were evaluated using the one-sample Wilcoxon signed rank test. For analyses involving changes in cyst volumes, the median % change in cyst volume per patient was assessed. Longitudinal changes in cyst volumes were assessed using linear mixed models. Changes in quality of life (QOL) [Linear Analog Self-Assessment (LASA), Polycystic Liver Disease Quality of life Questionnaire (PLD-Q) and 12-item short-form (SF12)] were also assessed.

Results

There were 102 SFS sessions (38 kidney, 58 liver, 6 combined liver/kidney cysts) performed on 77 unique individuals included for analysis. Median [interquartile range (IQR)] % reductions in TKCV were –92.0% (IQR –98.2%, –82.7%, P < .001) and for TLCV were –83.1% (IQR –93.5%, –52.9%, P < .001). Among patients with multiple kidney procedures (n = 7), median % reduction in TKCV was –94.3% (IQR –96.6%, –92.4%, P = .023). For patients with multiple liver procedures (n = 11), median % reduction in TLCV was –63.3% (IQR –85.2%, –28.3%, P = .004). Results were similar among the four patients undergoing multi-stage procedures (n = 1 kidney, n = 3 liver). When measured longitudinally, both liver and kidney cyst volumes declined to levels near 0 mL by 1 year follow-up and remained stable several years later. LASA physical domain and PLD-Q QOL scores improved post-SFS procedure.

Conclusion

SFS led to substantial long-term reductions in TKCV/TLCV and improved QOL. SFS can augment cyst volume reduction in addition to tolvaptan (kidney cysts) and octreotide (liver cysts). In some individuals with large symptomatic cysts, multiple SFS procedures were safe and effective in reducing TLCV/TKCV and improving symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SclerotherapyPolycystic Kidney, Autosomal DominantCystsLiver DiseasesQuality of LifeSclerosing SolutionsHumansMaleRetrospective StudiesFemaleMiddle AgedAdultFollow-Up StudiesPrognosisAged

Stichwörter der Autor:innen

kidney cystsliver cystspolycystic kidney diseasepolycystic liver diseasesclerotherapy

Substanzen

Sclerosing Solutions

Autor:innen und Institutionen

  • Radiology Department, Mayo Clinic, Rochester, MN, USA.
  • Division of Nephrology & Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Division of Nephrology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA.
  • Radiology Research, Mayo Clinic, Rochester, MN, USA.
  • Division of Clinical Trials and Biostatistics, Health Sciences Research, Biostatistics, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Marie C Hogan

Förderung

  • NCATS NIH HHS
  • Mayo Clinic
  • National Center for Advancing Translational Sciences

Zitieren

APA

Neidert, N., Kseibi, F., Martin, W. P., Bugazia, S., Bendel, E., Howe, C., Helland, R., Gregory, A., Liestikow, K., Kline, T., Vaughan, L., Torres, V. E., & Hogan, M. C. (2025). Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf111

Vancouver

Neidert N, Kseibi F, Martin WP, Bugazia S, Bendel E, Howe C, et al. Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf111

BibTeX
@article{Neidert2025,
  author = {Neidert, Newton and Kseibi, Firas and Martin, William P and Bugazia, Seif and Bendel, Emily and Howe, Cassie and Helland, Ryan and Gregory, Adriana and Liestikow, Kathleen and Kline, Timothy and Vaughan, Lisa and Torres, Vicente E and Hogan, Marie C},
  title = {Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf111}
}
Kostenlos starten →